ClinicalTrials.gg
CompletedNCT00422422Updated Jul 11, 2018Results posted

Open-label, Pharmacokinetic, Safety and Efficacy Study of Adjunctive Brivaracetam in Children With Epilepsy.

A Phase 2 interventional study of Brivaracetam in Epilepsy, sponsored by UCB Pharma. Completed at 39 sites in 6 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2018-07-11.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
1 Month to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing brivaracetam in Epilepsy — 2 open to participants now, 2 under way, 1 of them phase 3. brivaracetam · Epilepsy.

Enrollment
17th of 34
100 · median 94
Started
2011
with 3 others
Phase 2
6 of 34
none open now
Registered
6th of 34
by date
Lead sponsor
13 of 34
UCB Pharma

Among the 34 studies testing brivaracetam in Epilepsy, this one is the 17th largest by enrollment, is one of 4 that started in 2011, is one of 6 in phase 2, and was the 6th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 34 studies testing brivaracetam in Epilepsy are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About brivaracetam

brivaracetam: first FDA approval 2016 (BRIVIACT), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 1 Month to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing brivaracetam in Epilepsy, or all of them as a file.
02

Study summary

Initial study in children with epilepsy to evaluate the pharmacokinetics, safety, tolerability and preliminary efficacy of adjunctive treatment with brivaracetam, and to develop dosing adaptations for future studies.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Brivaracetam
  • Epilepsy
  • Child
  • Pharmacokinetics
  • Adolescents
04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of epilepsy
  • Subject having at least 1 seizure (any type) during the 3 weeks before first visit
  • Stable dosing of 1-3 concomitant antiepileptic drugs

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing females
  • Concomitant use of Levetiracetam
  • Epilepsy secondary to a Progressive cerebral disease/tumor or other neurodegenerative disease
  • History of status epilepticus
  • acute or chronic illness, underlying disease or medication condition
  • History of suicide attempt
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Brivaracetam

    Drug: Brivaracetam

Interventions

  • Oral solution Evaluation period (3 weeks up-titration): For subjects ≥8 years: * \~0.4 mg/kg bid for Week 1 * \~0.8 mg/kg bid for Week 2 * \~1.6 mg/kg bid for Week 3 For subjects \<8 years: * \~0.5 mg/kg bid for Week 1 * \~1.0 mg/kg bid for Week 2 * \~2.0 mg/kg bid for Week 3 Down-titration period (up to 2 weeks): For subjects ≥8 years: * \~0.8 mg/kg bid for Week 4 * \~0.4 mg/kg bid for Week 5 For subjects \<8 years: * \~1.0 mg/kg bid for Week 4 * \~0.5 mg/kg bid for Week 5

06

What researchers measure

Primary outcomes

  1. Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years

    Time frame: Day 21

  2. Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to <12 Years

    Time frame: Day 21

  3. Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to <16 Years

    Time frame: Day 21

  4. Mean Max Plasma Concentration for Age Range ≥1 Month to <2 Years

    Time frame: Day 21

  5. Mean Max Plasma Concentration for Age Range ≥2 to <12 Years

    Time frame: Day 21

  6. Mean Max Plasma Concentration for Age Range ≥12 to <16 Years

    Time frame: Day 21

Secondary outcomes

  1. Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period

    Time frame: Baseline to end of the 3-week evaluation period

  2. Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period

    Time frame: Baseline to end of the 3-week evaluation period

  3. Percent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period

    Time frame: Baseline to the end of the 3-week evaluation period

07

Results

Posted Jan 9, 2017

Participant flow

The N01263 study began recruitment in July 2011, with subjects enrolled in the European Union, Mexico, and the United States. The study concluded in March 2013.

Participant flow — Overall Study
MilestoneBrivaracetam (ES)
Started100
Completed90
Not completed10
Withdrew: Lack of efficacy1
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject2
Withdrew: Sae, non-fatal1
Withdrew: Ae, non-serious non-fatal5

Outcome measures

PrimaryMean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years
Time frame:
Day 21
Reported as:
Mean · ug/mL
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years
ug/mLBrivaracetam (PPS)
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥1 Month to <2 Years0.825 ± 0.826
PrimaryMean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to <12 Years
Time frame:
Day 21
Reported as:
Mean · ug/mL
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to <12 Years
ug/mLBrivaracetam (PPS)
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥2 to <12 Years0.967 ± 0.536
PrimaryMean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to <16 Years
Time frame:
Day 21
Reported as:
Mean · ug/mL
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to <16 Years
ug/mLBrivaracetam (PPS)
Mean Trough Plasma Concentration at 3rd Level for Age Range ≥12 to <16 Years1.117 ± 0.400
PrimaryMean Max Plasma Concentration for Age Range ≥1 Month to <2 Years
Time frame:
Day 21
Reported as:
Mean · ug/mL
Mean Max Plasma Concentration for Age Range ≥1 Month to <2 Years
ug/mLBrivaracetam (PPS)
Mean Max Plasma Concentration for Age Range ≥1 Month to <2 Years2.071 (0.320 to 4.305)
PrimaryMean Max Plasma Concentration for Age Range ≥2 to <12 Years
Time frame:
Day 21
Reported as:
Mean · ug/mL
Mean Max Plasma Concentration for Age Range ≥2 to <12 Years
ug/mLBrivaracetam (PPS)
Mean Max Plasma Concentration for Age Range ≥2 to <12 Years2.673 (0.561 to 5.418)
PrimaryMean Max Plasma Concentration for Age Range ≥12 to <16 Years
Time frame:
Day 21
Reported as:
Mean · ug/mL
Mean Max Plasma Concentration for Age Range ≥12 to <16 Years
ug/mLBrivaracetam (PPS)
Mean Max Plasma Concentration for Age Range ≥12 to <16 Years2.861 (2.627 to 3.371)
SecondaryNumber of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period
Time frame:
Baseline to end of the 3-week evaluation period
Reported as:
Number · participants
Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period
participantsBrivaracetam (SS)
Number of Subjects With at Least One Treatment-emergent Adverse Event Reported During the 3-week Evaluation Period66
SecondaryNumber of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period
Time frame:
Baseline to end of the 3-week evaluation period
Reported as:
Number · participants
Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period
participantsBrivaracetam (FAS)
Number of Subjects With a 50 % Reduction in Seizures Based on Seizure Diary Data From Baseline to End of the 3-week Evaluation Period17
SecondaryPercent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period
Time frame:
Baseline to the end of the 3-week evaluation period
Reported as:
Number · participants
Percent Compliance With Brivaracetam Oral Solution During the 3-week Evaluation Period
participantsBrivaracetam (SS)
<80 %5
80 % to 120 %90
>120 %2

Adverse events

Collected over Treatment-emergent Adverse Events (TEAEs) were collected during the course of the study up to day 49.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brivaracetam (SS)—8/99 (8.1%)33/99 (33.3%)
Most frequent serious events
Most frequent serious events
EventBrivaracetam (SS)
ConvulsionNervous system disorders4/99
DehydrationMetabolism and nutrition disorders2/99
DiarrhoeaGastrointestinal disorders1/99
PyrexiaGeneral disorders1/99
Otitis mediaInfections and infestations1/99
Respiratory tract infectionInfections and infestations1/99
ToxoplasmosisInfections and infestations1/99
Cytomegalovirus test positiveInvestigations1/99
Most frequent other events
Most frequent other events
EventBrivaracetam (SS)
IrritabilityGeneral disorders8/99
SomnolenceNervous system disorders8/99
PyrexiaGeneral disorders7/99
Decreased appetiteMetabolism and nutrition disorders7/99
ConvulsionNervous system disorders6/99
FatigueGeneral disorders5/99
PharyngotonsillitisInfections and infestations5/99

Baseline characteristics

Baseline Characteristics consists of the Enrolled Subjects analysis set, which is comprised of all subjects enrolled into the study.

Age, Continuous
Age, Continuous(years)Brivaracetam (ES)
Mean6.3 ± 4.8
Sex: Female, Male
Sex: Female, Male(Participants)Brivaracetam (ES)
Female51
Male49
Weight
Weight(kilograms)Brivaracetam (ES)
Mean24.2 ± 16.2
Height
Height(centimeters)Brivaracetam (ES)
Mean111.8 ± 32.9
BMI
BMI(kg/m^2)Brivaracetam (ES)
Median17.1 ± 3.4
Racial Group
Racial Group(participants)Brivaracetam (ES)
Black or African American4
White80
Other16
08

Study locations

39 sites
  • 108
    Gulf Breeze, Florida, United States
  • 110
    Miami, Florida, United States
  • 103
    Wellington, Florida, United States
  • 106
    Boston, Massachusetts, United States
  • 101
    Saint Paul, Minnesota, United States
  • 113
    Chesterfield, Missouri, United States
  • 105
    Buffalo, New York, United States
  • 104
    Rochester, New York, United States
  • 107
    Cincinnati, Ohio, United States
  • 114
    Pittsburgh, Pennsylvania, United States
  • 109
    Nashville, Tennessee, United States
  • 117
    Houston, Texas, United States
  • 202
    Brussels, Belgium
  • 203
    Brussels, Belgium
  • 201
    Leuven, Belgium
  • 502
    Hradec Kralove, Czechia
  • 504
    Ostrava Porubo, Czechia
  • 501
    Praha 4, Czechia
  • 602
    Aguascalientes, Mexico
  • 611
    Chihuahua, Mexico
  • 609
    Ciuliacan, Mexico
  • 603
    Guadalajara, Mexico
  • 604
    Mexico D.F., Mexico
  • 610
    Monterrey, Mexico
  • 607
    San Luis Potosi, Mexico
  • 404
    Bialystok, Poland
  • 403
    Gdansk, Poland
  • 406
    Kielce, Poland
  • 402
    Krakow, Poland
  • 401
    Poznan, Poland
  • 408
    Rzeszow, Poland
  • 407
    Szczecin, Poland
  • 405
    Wroclaw, Poland
  • 309
    Barcelona, Spain
  • 306
    Madrid, Spain
  • 301
    Palma de Mallorca, Spain
  • 304
    Santander, Spain
  • 308
    Valencia, Spain
  • 303
    Zaragoza, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2011, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 3 years 10 months after primary completion. A results delay was requested in Mar 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2007
First posted
Jan 17, 2007
Start
Jul 2011
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results delay requested
Mar 18, 2014
Results first posted
Jan 9, 2017
Last update
Jul 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00422422
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 17, 2007
Start date
Jul 2011
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jan 9, 2017
Last update
Jul 11, 2018

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brivaracetam

Start the discussion